<DOC>
	<DOCNO>NCT00104234</DOCNO>
	<brief_summary>The purpose study evaluate long-term efficacy safety rhASB treatment patient Mucopolysaccharidosis VI .</brief_summary>
	<brief_title>Study rhASB Patients With Mucopolysaccharidosis VI</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Patient consent Patient must successfully complete study ASB0305 , include receive least 20 24 scheduled weekly infusion miss two consecutive infusion If female childbearing potential , patient must negative pregnancy test Pregnant lactating patient Patient receive investigational drug within 30 day prior study enrollment Patient unwilling unable travel primary site periodic assessment</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>